Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer
(1993) In Gynecologic Oncology 48(1). p.38-49- Abstract
The Swedish Tumor Registries are population based. Three hundred eighty-four patients with epithelial ovarian cancer registered in the Tumor Registry of the Southeast Health Care Region during the years 1984 to 1987 were reviewed; 332 patients were eligible for survival analysis. The protocol treatment during this period included primary surgery aimed at tumor reduction followed by combination chemotherapy (anthracyclin + cis-platinum, AP) in FIGO stages IC-IV. All patients treated otherwise were registered as prescribed nonprotocol treatment. An overall corrected 5-year survival of 40% was recorded. However, only 166/325 of the patients (51%) were actually prescribed protocol treatment as defined above. The 5-year survival was 49% for... (More)
The Swedish Tumor Registries are population based. Three hundred eighty-four patients with epithelial ovarian cancer registered in the Tumor Registry of the Southeast Health Care Region during the years 1984 to 1987 were reviewed; 332 patients were eligible for survival analysis. The protocol treatment during this period included primary surgery aimed at tumor reduction followed by combination chemotherapy (anthracyclin + cis-platinum, AP) in FIGO stages IC-IV. All patients treated otherwise were registered as prescribed nonprotocol treatment. An overall corrected 5-year survival of 40% was recorded. However, only 166/325 of the patients (51%) were actually prescribed protocol treatment as defined above. The 5-year survival was 49% for patients prescribed protocol treatment compared to 33% for those prescribed nonprotocol treatment (P < 0.0001). Stages III-IV patients prescribed protocol treatment had 23% 5-year survival compared to 11% for patients prescribed nonprotocol treatment (P < 0.0001). The impact of cis-platinum-based combination chemotherapy was thus not as pronounced as expected from clinical studies since many patients were not considered to be in a good enough general condition to receive cis-platinum. Multivariate Cox analysis of 223 cases showed that age (P < 0.0001), stage (P = 0.0002), grade of differentiation (P = 0.006), and postoperative residual tumor (P = 0.007) were independent prognostic factors. A prognostic index was developed which divided the patients into different risk groups. It was shown that high-risk patients identified by this index were mainly found in the group prescribed nonprotocol treatment and that the prognostic index could not be used to identify patients with a low probability of response among patients prescribed protocol treatment.
(Less)
- author
- Högberg, T LU ; Carstensen, J and Simonsen, E
- publishing date
- 1993-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Adult, Age Factors, Aged, Aged, 80 and over, Carcinoma/pathology, Combined Modality Therapy, Female, Humans, Middle Aged, Multivariate Analysis, Neoplasm Staging, Ovarian Neoplasms/pathology, Prognosis, Survival Analysis, Treatment Outcome
- in
- Gynecologic Oncology
- volume
- 48
- issue
- 1
- pages
- 12 pages
- publisher
- Academic Press
- external identifiers
-
- scopus:0027473723
- pmid:8423020
- ISSN
- 0090-8258
- DOI
- 10.1006/gyno.1993.1007
- language
- English
- LU publication?
- no
- id
- 60d284ec-ee46-45ca-8add-6ab8d66ac083
- date added to LUP
- 2019-09-20 08:14:27
- date last changed
- 2024-01-01 20:57:20
@article{60d284ec-ee46-45ca-8add-6ab8d66ac083,
abstract = {{<p>The Swedish Tumor Registries are population based. Three hundred eighty-four patients with epithelial ovarian cancer registered in the Tumor Registry of the Southeast Health Care Region during the years 1984 to 1987 were reviewed; 332 patients were eligible for survival analysis. The protocol treatment during this period included primary surgery aimed at tumor reduction followed by combination chemotherapy (anthracyclin + cis-platinum, AP) in FIGO stages IC-IV. All patients treated otherwise were registered as prescribed nonprotocol treatment. An overall corrected 5-year survival of 40% was recorded. However, only 166/325 of the patients (51%) were actually prescribed protocol treatment as defined above. The 5-year survival was 49% for patients prescribed protocol treatment compared to 33% for those prescribed nonprotocol treatment (P < 0.0001). Stages III-IV patients prescribed protocol treatment had 23% 5-year survival compared to 11% for patients prescribed nonprotocol treatment (P < 0.0001). The impact of cis-platinum-based combination chemotherapy was thus not as pronounced as expected from clinical studies since many patients were not considered to be in a good enough general condition to receive cis-platinum. Multivariate Cox analysis of 223 cases showed that age (P < 0.0001), stage (P = 0.0002), grade of differentiation (P = 0.006), and postoperative residual tumor (P = 0.007) were independent prognostic factors. A prognostic index was developed which divided the patients into different risk groups. It was shown that high-risk patients identified by this index were mainly found in the group prescribed nonprotocol treatment and that the prognostic index could not be used to identify patients with a low probability of response among patients prescribed protocol treatment.</p>}},
author = {{Högberg, T and Carstensen, J and Simonsen, E}},
issn = {{0090-8258}},
keywords = {{Adult; Age Factors; Aged; Aged, 80 and over; Carcinoma/pathology; Combined Modality Therapy; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Staging; Ovarian Neoplasms/pathology; Prognosis; Survival Analysis; Treatment Outcome}},
language = {{eng}},
number = {{1}},
pages = {{38--49}},
publisher = {{Academic Press}},
series = {{Gynecologic Oncology}},
title = {{Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer}},
url = {{http://dx.doi.org/10.1006/gyno.1993.1007}},
doi = {{10.1006/gyno.1993.1007}},
volume = {{48}},
year = {{1993}},
}